. This article belongs to one of his conferences and is an expanded abstract of his talk, to which he has added the most important references that he used at the conference. The approach of almost all current cancer therapies is essentially the same as those practiced by the Greeks and Romans, namely, to remove cancer tissues at a stage early enough to prevent cancer from overwhelming the body. While initial treatment regimens are often based on specific genomic data and are effective in many cases, they can sometimes be followed, usually after a period, by the reoccurrence of cancer as untreatable metastatic disease1, often with poor prognoses due to treatment resistance2.
The approach of almost all current cancer therapies is essentially the same as those practiced by the Greeks and Romans, namely, to remove cancer tissues at a stage early enough to prevent cancer from overwhelming the body. While initial treatment regimens are often based on specific genomic data and are effective in many cases, they can sometimes be followed, usually after a period, by the reoccurrence of cancer as untreatable metastatic disease 1 , often with poor prognoses due to treatment resistance 2 . Over the past several years generating actionable genomic data has become more complicated with the discovery of intra-tumor genetic heterogeneity (ITGH) 3 . Indeed, in the case of metastatic disease, it has been proposed that genetic and epigenetic heterogeneity has contributed to the inability to successfully eradicate the disease 4 . This has resulted in some questioning as to whether precision medicine can really be the treatment panacea that it is claimed to be 5 . Further, most genomic markers have so far provided only limited insight into the mechanisms that control both carcinogenesis and metastasis, perhaps because current cancer hypotheses fail to provide an adequate framework with which to analyze the data. Therefore, to overcome these problems, a new hypothesis has been proposed based on the premise that cancer can be considered a tissue survival strategy and that post-zygotic mosaicism associated with ITGH allows tissues to survive changing environmental conditions 10 . Further, many of these somatic mutations would arise relatively early in human fetal development, presumably to prepare organisms to survive environmental changes that they might encounter throughout their lifetime.
Indeed, early genetic heterogeneity has now been observed in fetal cells 11, 12 . Thus, the hypothesis could explain why genetic heterogeneity of cancer-associated genes has been observed in normal tissues 13, 14 , and why, post-zygotic single nucleotide mosaicism of cancer-associated genes exists in small numbers of cells in both diseased and normal individuals 15 .
The hypothesis further suggests a selection-centric approach to cancer treatment that has been labeled as 'strength-based'. This approach considers selection pressures caused by tissue microenvironments to be the critical factors in carcinogenesis and metastasis, rather than the accumulation of mutation-based phenotypic changes. The key from a treatment standpoint is the evidence that normal cells with wild-type genes exist in tumors, albeit in very small numbers.
Similarly, cells present in normal tissues that surround tumors can contain cancer-associated mutant variant genes. Therefore, rather than just removing cancer tissues, we should promote the selection of normal cells within cancerous tissues. Therefore, if we can create tissue microenvironmental conditions that select normal cells we can change cancerous tissues back to normal, as well as make it highly unlikely that the cancer will return. A selection-centric approach to treating metastatic disease would similarly focus on preventing the growth of metastases, by ensuring that metastatic cells are not selected for by their tissue microenvironments. Recent evidence has begun to provide some support for this radical treatment approach by examining the possible effects of tissue microenvironments on cancer tissues 16, 17 .
Almost all studies up until now have examined associations between environmental factors and cancer development, but not specifically of tissue microenvironments, although the importance of studying these relationships has been acknowledged 18 . Recently there has been an increased effort to identify what these factors might be in cancer tissues. Tools such as mass spectroscopy have allowed increased attention to be given to the carcinogenic role of the tumor microenvironment including in both tumorigenesis 19 and differential tissue responses to therapy 20 . However, as cells and tissues exist in complex three-dimensional environments, and contain both extra-and intracellular components, to fully analyze these environments will require new technologies including; atomic force microscopy 21 , quantitative extracellular matrix proteomics 22 , and single cell analysis 23 . Finally, analysis of the effects of micro-environmental selection pressures on tissues and cells will also require the development of much more sophisticated genetic databases than presently exist 24 .
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